US › Healthcare

Carisma Therapeutics Inc. (CARM)

US · Healthcare · Biotechnology

$0.000.00%

Last close · 2026-08-04

Latest quarter · ended 2025-09-30

Revenue

$45.2M

Revenue YoY

+1236.8%

Net profit

$44.7M

Profit YoY

+452.0%

EPS

$1.07

EPS estimate

$-0.57

Net margin

98.8%

EPS came in at 1.07 against a street estimate of -0.57 — a beat of 287.7%.

Key statistics

Market cap

$104,612

P/E

0.0

Forward P/E

0.0

P/B

114.10

Book value

$-0.02

EPS (TTM)

$0.19

52-week high

$0.56

52-week low

$0.00

50-day MA

$0.01

200-day MA

$0.03

Beta

-29.69

Analyst view

Analysts rate Carisma Therapeutics Inc. a buy (1 buy, 1 hold, 0 sell out of 2) with an average price target of $1.00.

Shareholding

Insiders

26.56%

Institutions

10.79%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Carisma Therapeutics Inc. — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Novo Nordisk A/S Amgen Inc Abbott Laboratories Gilead Sciences Inc

Data updated 2026-08-05.